MENU
Important Safety Information: GATTEX may cause serious side effects including making abnormal cells grow faster, polyps in the colon (large intestine), blockage of the bowels (intestines), swelling (inflammation) or blockage of your gallbladder or pancreas, and fluid overload. Click here for additional Important Safety Information.

Support for Your Patients

GATTEX® Patient Support Programs

Hypothetical patient portrayal

 

Let your patients know that a network of support exists for people with Short Bowel Syndrome. Here are just a few of the organizations they might be interested in:

Facebook

Facebook offers a number of support groups, including:

 

NORD Foundation

NORD (National Organization for Rare Disorders, Inc.) has been empowering the rare disease community for more than 30 years.

OLEY Foundation 

This organization is dedicated to enriching the lives of those requiring home IV and tube feeding through education, outreach and networking.

Global Genes 

Global Genes is one of the leading rare disease patient advocacy organizations in the world.

Crohn’s & Colitis Foundation of America 

The Crohn's & Colitis Foundation of America (CCFA) is a non-profit, volunteer-driven organization dedicated to finding the cures for Crohn's Disease and ulcerative colitis.

United Ostomy Association of America 

We invite you to explore this website to find information about ostomies.

International Federation of Functional Gastrointestinal Disorders 

An educational resource for reliable digestive health knowledge, support, and assistance about functional gastrointestinal (GI) and motility disorders (FGIMDs).

SBS Foundation 

This organization provides education, support and advocacy services for the short bowel community.

Some of the websites listed here allow for free exchange of information (for example, chat rooms and forums). Shire does not sponsor or endorse this free exchange of information. Shire is not responsible for the content or services provided by any websites that are not owned by Shire. Websites that are not owned by Shire are governed by their own polices and guidelines, including privacy policies.

 

Important Safety Information

Warnings and Precautions

Neoplastic growth
Colorectal polyps were identified during clinical trials. There is a risk for acceleration of neoplastic growth. Colonoscopy of the entire colon with removal of polyps should be done within 6 months prior to starting treatment with GATTEX and is recommended after 1 year. Subsequent colonoscopies should be done as needed, but no less frequently than every 5 years. In case of intestinal malignancy (GI tract, hepatobiliary, pancreatic), discontinue GATTEX. The clinical decision to continue GATTEX in patients with non‑gastrointestinal malignancy should be made based on risk and benefit considerations.

Intestinal obstruction
Intestinal obstruction has been reported in clinical trials. In patients who develop obstruction, GATTEX should be temporarily discontinued pending further clinical evaluation and management.

Biliary and pancreatic disease
Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical trials. Patients should undergo laboratory assessment (bilirubin, alkaline phosphatase, lipase, amylase) before starting GATTEX. Subsequent laboratory tests should be done every 6 months. If clinically meaningful changes are seen, further evaluation is recommended including imaging, and continued treatment with GATTEX should be reassessed.

Fluid overload
Fluid overload and congestive heart failure have been observed in clinical trials. There is potential for fluid overload while on GATTEX. If fluid overload occurs, especially in patients with underlying cardiovascular disease, parenteral support should be appropriately adjusted and GATTEX treatment reassessed.

Increased absorption of concomitant oral medication
Altered mental status in association with GATTEX has been observed in patients on benzodiazepines in clinical trials. Patients on concomitant oral drugs (e.g. benzodiazepines, phenothiazines) requiring titration or with a narrow therapeutic index may require dose adjustment while on GATTEX.

Adverse Reactions
The most common adverse reactions (≥10%) across all studies with GATTEX are abdominal pain, injection site reactions, nausea, headaches, abdominal distension, upper respiratory tract infection. In addition, vomiting and fluid overload were reported in the SBS studies (1 and 3) at rates ≥10%.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088. You can also call Shire at 1‑855‑5GATTEX (1-855-542-8839).

GATTEX (teduglutide [rDNA origin]) for injection is indicated for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

For additional safety information, please click here for Prescribing Information